BioSpace News Archive

Solve Therapeutics, Inc. (SolveTx), an oncology-focused biopharmaceutical company, announced today its mission to develop novel antibody-based therapies targeting tumor-specific antigens.

Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, reported today that dosing with ALG-125755, a small interfering RNA (siRNA) targeting the production of hepatitis B surface antigen (HBsAg), was initiated in subjects with chronic hepatitis B (CHB) in Study ALG-125755-501 (NCT05561530).

Syndax Pharmaceuticals, Inc. announced the closing of its previously announced underwritten public offering of 7,840,909 shares of its common stock at a price to the public of $22.00 per share.

Novavax, Inc., a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, announced a proposed offering of $125 million aggregate principal amount of convertible senior notes due 2027.

CureVac N.V. announced that Chief Executive Officer Franz-Werner Haas, Chief Financial Officer Pierre Kemula and Interim Chief Development Officer Ulrike Gnad-Vogt sold an aggregate of 103,775 CureVac common shares.

Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA) today announced the U.S. Food and Drug Administration (FDA) has cleared Biomea’s IND application for BMF-219 in type 2 diabetes to support the expansion of the COVALENT-111 study to sites in the U.S.

Ra Medical Systems, Inc. announces that it has received notification from the NYSE American LLC that the Company has regained compliance with the NYSE American’s continued listing standard.

NewStem joins MSK Innovation Hub in collaboration to advance stem cell-based diagnostics that will increase cancer treatment efficacy

Life Spine, a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spinal disorders, announced today that it has received clearance from the U.S. Food & Drug Administration (FDA) to market the TruLift Lateral Expandable Spacer System and Lateral Plate System.

Everest Medicines announced that the company has achieved the preclinical proof-of-concept milestone for its mRNA rabies vaccine program.